Get the Stockscreener App
322.21
0.14%
-0.46
After Hours:
321.63
-0.58
-0.18%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $322.21, with a volume of 1.83M.
It is down -0.14% in the last 24 hours and down -3.48% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$322.67
Open:
$321.32
24h Volume:
1.83M
Relative Volume:
0.99
Market Cap:
$172.43B
Revenue:
$30.93B
Net Income/Loss:
$3.13B
P/E Ratio:
22.90
EPS:
14.07
Net Cash Flow:
$5.48B
1W Performance:
-3.99%
1M Performance:
-3.48%
6M Performance:
+13.33%
1Y Performance:
+19.89%
1-Day Range:
$318.79
$323.23
1-Week Range:
$312.16
$335.41
52-Week Range:
$249.70
$346.85
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Amgen must face lawsuit claiming it hid $10.7 billion tax bill - Yahoo Finance
Biocon Pushes to Unseal Amgen Eylea Court Filings Before Appeal - Bloomberg Law
Amgen, Family Heart Foundation launch at-home cholesterol screening for LDL-C Awareness Day - MM+M Online
NASDAQ: AMGN Lawsuit Notice: Investors in shares of Amgen Inc. (NASDAQ: AMGN) should contact the Shareholders Foundation - PR Newswire
NASDAQ: AMGN Lawsuit Notice: Investors in shares of Amgen Inc. (NASDAQ: AMGN) should contact the Shareholders Foundation - Morningstar
Amgen Inc. (NASDAQ:AMGN) Short Interest Update - MarketBeat
Duff & Phelps Investment Management Co. Reduces Stock Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc. (AMGN): Hedge Fund Interest and Strong Pipeline Support Moderate Buy Rating - Insider Monkey
Amgen Inc. (AMGN): Hedge Fund Interest and Strong Pipeline Support Moderate Buy Rating - Yahoo Finance
Northeast Financial Consultants Inc Sells 350 Shares of Amgen Inc. (NASDAQ:AMGN) - Defense World
Amgen Inc. (NASDAQ:AMGN) to Post FY2024 Earnings of $19.48 Per Share, Cantor Fitzgerald Forecasts - MarketBeat
Prescription For Dividends: Why Amgen Is More Than Just A Safe Bet (NASDAQ:AMGN) - Seeking Alpha
Texas Capital Bank Wealth Management Services Inc Buys New Shares in Amgen Inc. (NASDAQ:AMGN) - Defense World
Amgen Inc. (NASDAQ:AMGN) Shares Sold by Susquehanna Portfolio Strategies LLC - Defense World
Buck Wealth Strategies LLC Makes New $7.17 Million Investment in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases - MSN
Cantor highly bullish on Amgen obesity drug, starts coverage at overweight - MSN
Amgen Lifts Obesity Investment as Sales Beat Estimates - MSN
Amgen Inc. (NASDAQ:AMGN) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Amgen initiated with an Overweight at Cantor Fitzgerald - Yahoo Finance
Mackenzie Financial Corp Sells 27,798 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen (AMGN) Ascends While Market Falls: Some Facts to Note - Yahoo Finance
Regeneron Shares Head for Worst Month Since 2019 on Legal Ruling - Bloomberg
Federman & Sherwood Investigates Amgen, Inc. for Data Breach - Business Wire
Amgen, Chevron share gains lead Dow's 213-point jump - MSN
Amgen, Chevron share gains lead Dow's 213-point jump - MarketWatch
Amgen Announces Third-party Data Breach Stemming from Incident at Sirva Relocation - JD Supra
Statin Market Expecting Huge Demand in Upcoming Years |Amgen, Biocon, AstraZeneca, Novartis - openPR
Regeneron Shares Head for Worst Month Since 2019 on Legal Ruling - BNN Bloomberg
Cantor highly bullish on Amgen obesity drug, starts coverage at overweight (NASDAQ:AMGN) - Seeking Alpha
Amgen (NASDAQ:AMGN) Now Covered by Cantor Fitzgerald - MarketBeat
Amgen Inc. (AMGN): An Undervalued Wide Moat Stock to Buy According to Analysts - Insider Monkey
Amgen Inc. (AMGN): An Undervalued Wide Moat Stock to Buy According to Analysts - Yahoo Finance
Caxton Associates LP Has $739,000 Stock Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Prediction: Eli Lilly Will Dominate the Billion-Dollar Weight Loss Drug Market for This Key Reason - The Motley Fool
(AMGN) Technical Data - Stock Traders Daily
Amgen (NASDAQ:AMGN) Stock Quotes, Forecast and News Summary - Benzinga
Amgen Inc. stock outperforms competitors on strong trading day - MarketWatch
AMGN Stock Falls Despite Upbeat Data on Immunology Drugs: Here's Why - Yahoo Finance
Amgen: Pipeline Updates, Uplizna Performs And Rocatinlimab Underwhelms - Seeking Alpha
Amgen updates underwhelm investors - The Pharma Letter
Daymark Wealth Partners LLC Raises Stock Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Stock Falls on Disappointing Drug Data - The Wall Street Journal
Amgen Delivers Mixed Data For Rocatinlimab In Atopic Dermatitis, Uplizna In Myasthenia Gravis - Scrip
Amgen Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Amgen stock falls on lackluster drug data - Yahoo Finance
U.S. Patent Office Enablement Guidelines in View of Supreme Court Amgen v. Sanofi Decision - JD Supra
Amgen, Chevron share losses lead Dow's nearly 250-point drop - MarketWatch
Amgen stock slides 5% as analysts weigh in on drug study results (NASDAQ:AMGN) - Seeking Alpha
Dow's nearly 350-point fall led by losses for Amgen, Chevron shares - MSN
Amgen’s stock falls 4% as analysts say drug updates lag competitors - MarketWatch
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Amgen Inc Stock (AMGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Grygiel Nancy A. | SVP & CCO |
Dec 04 '23 |
Sale |
273.03 |
2,096 |
572,276 |
10,874 |
| Graham Jonathan P | EVP, Gen. Counsel & Secy. |
Nov 08 '23 |
Sale |
272.81 |
10,000 |
2,728,136 |
28,078 |
0.52%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):